|
Inclusion criteria | (1) Subjects aged 19–75 years |
(2) Subjects who meet the Rome III criteria for functional dyspepsia |
(3) Subjects with more than 40 points on the visual analog scale (VAS; 0, no discomfort; 100, most severe discomfort) for the severity of dyspeptic symptoms |
(4) Subjects who agree to receive no other treatments during the study |
(5) Subjects who voluntarily agree with the study protocol and sign a written informed consent |
|
Exclusion criteria | (1) Subjects with peptic ulcer or gastroesophageal reflux disease confirmed on esophagogastroduodenoscopy |
(2) Subjects with obvious signs of irritable bowel syndrome |
(3) Subjects with alarm symptoms, such as severe weight loss, melena, and dysphagia |
(4) Subjects with severe systemic organ diseases (cancer, diseases of heart, lung, liver, or kidney) or mental illness |
(5) Subjects who have had surgery related to the gastrointestinal tract, except for appendectomy more than six months ago |
(6) Subjects taking drugs that might affect the gastrointestinal tract; a minimum wash-out period of a week is required before participating in the study |
(7) Subjects who have had maxillofacial surgery or facial bone contouring surgery |
(8) Subjects who are pregnant or breastfeeding |
(9) Subjects who have malabsorption or maldigestion |
(10) Human immunodeficiency virus (HIV) positive subjects |
(11) Subjects with difficulties in taking part in the study (e.g., serious mental illness, dementia, drug addiction, time constraint, severe disorder in vision or hearing, illiteracy) |
(12) Subjects who have taken investigational drugs for other trials in the last three months |
|